Medical TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 millionBy Marie JonesAugust 13, 2021 CDMO Business Achieves Leapfrog Breakthrough Two Products Approved for Launch Smooth Progress of Various Core Anti-tumor Drugs Clinical Trials To…